TEVA Pharmaceuticals will
begin to take a share of Pfizer’s
blockbuster Viagra (sildenafil
citrate) sales as the US Food
and Drug Administration (FDA)
approved the first generic version
of the erectile dysfunction drug last
Wednesday.
Consumers will need to wait until
2017 though before they can see
savings with Teva spokeswoman
Denise Bradley telling Focus that
because of a 2013 pay-for-delay
settlement with Pfizer, the Israel based
company has agreed to not
launch the generic until Dec 2017.
Global generic giant Mylan
Pharmaceuticals, parent of
Alphapharm in Australia, also
agreed with Pfizer not to launch its
generic version of Viagra until 2017.
At least nine other generic
manufacturers have filed
abbreviated new drug applications
with FDA seeking approval for
their versions of generic Viagra,
according to the Regulatory Affairs
Professionals Society report on the
matter.The above article was sent to subscribers in Pharmacy Daily's issue from 14 Mar 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Mar 16
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.